Die Jahrestagung der amerikanischen Gesellschaft für Klinische Onkologie (ASCO) hat letzten Freitagmorgen begonnen und wird bis Dienstag, den 7. Juni, dauern.

Jeden Tag finden Vorträge über das multiple Myelom statt. Freitag wurden die meisten Vorträge mit neuen Forschungsergebnissen über das Myelom gehalten. Es gab neun Vorträge während einer einzelnen Nachmittagssitzung, die sich auf das multiple Myelom konzentrierten.

Außerdem gab es am Samstag, Sonntag und Montag Fortbildungssitzungen über das multiple Myelom. Darüber hinaus gab es am Sonntag eine Sitzung mit sogenannten late-braking abstracts (hochaktuellen Zusammenfassungen), die eine Präsentation über wichtige, neue Forschungsergebnisse über …

This year’s American Society of Clinical Oncology (ASCO) annual meeting began the morning of last Friday, and the meeting will run through Tues­day.

Multiple myeloma-related pre­sen­ta­tions are taking place every day of the meeting. Friday, how­ever, was the busiest day at the meeting in terms of oral pre­sen­ta­tions with new myeloma-related re­search. There were nine such pre­sen­ta­tions during a single afternoon session focused on multiple myeloma.

In addi­tion, there were myeloma-related education session pre­sen­ta­tions on Saturday, yesterday, and today. There also was a late-breaking ab­stract session yesterday (Sunday) with one pre­sen­ta­tion that …

Good morning, myeloma world.

We all should have seen this coming.

After days and days of having no major myeloma business news to cover here at Myeloma Morning, what hap­pens? Suddenly, there's not just one new myeloma-related business devel­op­ment to discuss. And not just two. But a full three such news items to review.

So let's start with those devel­op­ments, after which we'll take a quick look at a new research article and what's been going on in the Beacon's forum.

Initial Results Of Darzalex MMY3004 Clinical Trial

We …

PharmaMar intends to submit a Marketing Authorization Application to the European Medicines Agency during the last quarter of this year

Madrid (Press Release) – PharmaMar (MSE:PHM) today announced positive top-line results of its Phase III clin­i­cal trial -ADMYRE- with Aplidin® (plitidepsin) in combination with dexa­metha­sone versus dexa­metha­sone alone in patients with relapsed/refractory multiple myeloma (MM). Aplidin® has shown a statistically sig­nif­i­cant 35% reduction in the risk of pro­gres­sion or death over the com­parator (p=0.0054). The study has met its pri­mary end­point.

This pivotal, ran­dom­ized, open-label, inter­na­tional, multi­center Phase III clin­i­cal trial, called ADMYRE, en­rolled 255 patients in 83 medical …

The pivotal study will assess the efficacy of plitidepsin plus dexa­meth­a­sone versus dexamethasone alone in patients with re­lapsed / refractory multiple myeloma

Madrid (Press Release) – PharmaMar announced today that the patient recruitment for the pivotal Phase III trial of APLIDIN® (plitidepsin) for the treat­ment of multiple myeloma, denominated ADMYRE, has been suc­cessfully com­pleted. The study, which originally planned to in­clude 250 patients, has enrolled 255 patients in 71 medical centers world­wide, in­­clud­ing the US, Europe, Asia, South America, Australia, and New Zealand. An appli­ca­tion for market­ing authori­za­tion in Europe is planned to be submitted in 2016.

ADMYRE …

A Phase 2 clinical trial showed that plitidepsin alone had limited efficacy in heavily pretreated relapsed and refractory multiple myeloma patients. However, plitidepsin in combination with dexamethasone was effective enough to warrant further study. Plitidepsin alone or in combination with dexamethasone was well tolerated.

“Plitidepsin has not shown very significant efficacy when used in monotherapy,” explained Dr. María Mateos, the lead investigator of this study. “Nevertheless, in the present study we have seen some hints of activity in very heavily pretreated patients.”

Among the patients who received plitidepsin alone, 13 percent achieved …